David J. McConkey

50.8k total citations · 5 hit papers
385 papers, 27.3k citations indexed

About

David J. McConkey is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, David J. McConkey has authored 385 papers receiving a total of 27.3k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Molecular Biology, 154 papers in Surgery and 114 papers in Oncology. Recurrent topics in David J. McConkey's work include Bladder and Urothelial Cancer Treatments (150 papers), Urinary and Genital Oncology Studies (74 papers) and Cell death mechanisms and regulation (47 papers). David J. McConkey is often cited by papers focused on Bladder and Urothelial Cancer Treatments (150 papers), Urinary and Genital Oncology Studies (74 papers) and Cell death mechanisms and regulation (47 papers). David J. McConkey collaborates with scholars based in United States, Sweden and Canada. David J. McConkey's co-authors include Sten Orrenius, Pierluigi Nicotera, Colin P. Dinney, Pia Hartzell, Mikael Jondal, Woonyoung Choi, James L. Abbruzzese, Darren W. Davis, Giorgio Bellomo and Arlene O. Siefker‐Radtke and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David J. McConkey

372 papers receiving 26.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

2014 1.2k citations Woonyoung Choi, Sima P. Porten et al. profile →
Role of Ca2+ in toxic cell killing

1989 733 citations David J. McConkey et al. profile →
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

2009 729 citations Thiruvengadam Arumugam, Vijaya Ramachandran et al. Cancer Research profile →
Autophagy as a target for anticancer therapy

2011 680 citations David J. McConkey et al. profile →
Molecular profile of bladder cancer progression to clinically aggressive subtypes

2024 38 citations Woonyoung Choi, David J. McConkey et al. profile →

Peers

Countries citing papers authored by David J. McConkey

Since Specialization

Citations

This map shows the geographic impact of David J. McConkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. McConkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. McConkey more than expected).

Fields of papers citing papers by David J. McConkey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. McConkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. McConkey. The network helps show where David J. McConkey may publish in the future.

Co-authorship network of co-authors of David J. McConkey

This figure shows the co-authorship network connecting the top 25 collaborators of David J. McConkey. A scholar is included among the top collaborators of David J. McConkey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. McConkey. David J. McConkey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer 2025 ·Cancer Research Communications ·Evangelia Vlachou, Burles A. Johnson, David J. McConkey, Noah M. Hahn, Yuezhou Jing, Stephanie Russell, (unknown), Antony Rosen, Livia Casciola‐Rosen, Jean Hoffman‐Censits	0
2	Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial 2024 ·European Urology ·Elizabeth R. Plimack, Catherine M. Tangen, Melissa Plets, (unknown), Joanne Xiu, Chadi Nabhan, Eric A. Ross, (unknown), Woonyoung Choi, (unknown), (unknown), (unknown), M. Scott Lucia, Siamak Daneshmand, Dan Theodorescu, Amir Goldkorn, Seth P. Lerner, Thomas W. Flaig, David J. McConkey	7
3	Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model 2024 ·Frontiers in Immunology ·(unknown), (unknown), Alberto Martini, (unknown), Ganiraju C. Manyam, Yan Chen, Anil K. Sood, (unknown), Burles A. Johnson, Bogdan Czerniak, Byron Lee, Chinnaswamy Jagannath, Seppo Ylä‐Herttuala, Nigel Parker, David J. McConkey, Colin P. Dinney, Sharada Mokkapati	2
4	Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 2023 ·European Urology ·Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner	48
5	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) 2021 ·Clinical Cancer Research ·Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson	58
6	γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer 2021 ·Cancer Immunology Research ·Niannian Ji, Neelam Mukherjee, (unknown), (unknown), Joshua J. Meeks, David J. McConkey, Jonathan Gelfond, Tyler J. Curiel, Robert S. Svatek	15
7	Mutational Landscape and Environmental Effects in Bladder Cancer 2020 ·International Journal of Molecular Sciences ·Takuji Hayashi, Kazutoshi Fujita, Yujiro Hayashi, Koji Hatano, Atsunari Kawashima, David J. McConkey, Norio Nonomura	31
8	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer 2020 ·Molecular Cancer Research ·Sharada Mokkapati, Sima P. Porten, Vikram M. Narayan, (unknown), Isuru Jayaratna, Beat Roth, Tiewei Cheng, Neema Navai, Matthew Wszolek, Jonathan Melquist, Ganiraju C. Manyam, Woonyoung Choi, Bradley M. Broom, Shanna Pretzsch, Bogdan Czerniak, David J. McConkey, Colin P. Dinney	6
9	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer 2017 ·Cancer Immunology Research ·Max Kates, Thomas R. Nirschl, Nikolai A. Sopko, Hotaka Matsui, Christina M. Kochel, Leonardo Oliveira Reis, George J. Netto, Mohammad Obaidul Hoque, Noah M. Hahn, David J. McConkey, Alex S. Baras, Charles G. Drake, Trinity J. Bivalacqua	56
10	Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer 2017 ·Clinical Cancer Research ·Max Kates, Abhijit A. Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, (unknown), Nikolai A. Sopko, Hotaka Matsui, Noah M. Hahn, David J. McConkey, Alexander S. Baras, Justin Hanes, Laura M. Ensign, Trinity J. Bivalacqua	47
11	Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin 2012 ·Cancer Research ·Russell R. Braeuer, Maya Zigler, Takafumi Kamiya, Andrey S. Dobroff, Li Huang, Woonyoung Choi, David J. McConkey, Einav Shoshan, Aaron K. Mobley, Renduo Song, Avraham Raz, Menashe Bar‐Eli	81
12	Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells 2011 ·Clinical Cancer Research ·Edmund Chiong, I-Ling Lee, Ali Dadbin, Anita L. Sabichi, (unknown), Diana L. Urbauer, David J. McConkey, Rian J. Dickstein, Tiewei Cheng, H. Barton Grossman	58
13	Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors 2010 ·Cancer Research ·(unknown), Keila E. Torres, Juehui Liu, Belinda Hernandez, Eric D. Young, Roman Belousov, Svetlana Bolshakov, Alexander J. Lazar, John M. Slopis, Ian E. McCutcheon, David J. McConkey, Dina Lev	64
14	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer breakdown → 2009 ·Cancer Research ·Thiruvengadam Arumugam, Vijaya Ramachandran, Keith F. Fournier, Huamin Wang, Lauren Marquis, James L. Abbruzzese, Gary E. Gallick, Craig D. Logsdon, David J. McConkey, Woonyoung Choi	729
15	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy 2009 ·Clinical Cancer Research ·Liana Adam, Meng Zhong, Woonyoung Choi, Qi Wei, Milena S. Nicoloso, Ameeta Arora, George A. Calin, Hua Wang, Arlene O. Siefker‐Radtke, David J. McConkey, Menashe Bar‐Eli, Colin P. Dinney	351
16	The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition 2009 ·Cancer Prevention Research ·David J. McConkey, Colin P. Dinney	2
17	Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells 2008 ·Clinical Cancer Research ·Xue Pan, Thiruvengadam Arumugam, Tameyoshi Yamamoto, (unknown), Vijaya Ramachandran, Baoan Ji, Gabriel Lopez‐Berestein, Pablo E. Vivas‐Mejía, Anil K. Sood, David J. McConkey, Craig D. Logsdon	105
18	Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells 2005 ·Cancer Research ·Steffan T. Nawrocki, Jennifer S. Carew, Kenneth Dunner, Lawrence Boise, Paul J. Chiao, Peng Huang, James L. Abbruzzese, David J. McConkey	260
19	Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells 2005 ·Cancer Research ·Wassim Kassouf, Colin P. Dinney, Gordon Brown, David J. McConkey, Alan J. Diehl, Menashe Bar‐Eli, Liana Adam	67
20	Inhibition of proliferation of PC3 cells by the branched‐chain fatty acid, 12‐methyltetradecanoic acid, is associated with inhibition of 5‐lipoxygenase 2003 ·The Prostate ·Peiying Yang, Peter D. Collin, Timothy Madden, Diana Chan, (unknown), David J. McConkey, Robert A. Newman	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact